Viridian Therapeutics (VRDN) earnings, Nov 4, 2026: EPS −138%, stock +15.5%
In brief
Viridian Therapeutics reported on Nov 4, 2026. Earnings per share changed −138% year over year, 20.2% above the estimate; revenue −64%. The stock opened with a +12.4% gap and closed the day +15.5% (Nov 4, 2026). The stock is now 16.7% below its 52-week high, +16.9% over 12 months. Next report: Mar 11, 2027.
EPS vs estimate+20.2%
EPS, YoY−138%
Revenue, YoY−64%
Gap · day+12.4% · +15.5%
EPS growth by quarter, YoY
Price reaction to earnings
| Report | Gap | Day |
|---|---|---|
| Aug 6, 2026 | +2.1% | +4.8% |
| Nov 4, 2026 | +12.4% | +15.5% |
Next-quarter estimates, ratings and the VRDN chart are in the terminal.
Open the terminalFAQ
When is Viridian Therapeutics's next earnings report?
Mar 11, 2027. The date comes from daily data and is corrected if the company moves it.
How did Viridian Therapeutics stock react to the report?
Opening gap +12.4%, day's result +15.5%.
Did Viridian Therapeutics's earnings grow?
Earnings per share fell 138% year over year.
What is an earnings gap?
The jump between the close before and the open after the report. A big gap up often means large buyers are revaluing the company.